Myocarditis

New England Journal of Medicine

Volumn 343, Issue 19, 2000, Pages 1388-1398

  Feldman, Arthur M ^a,b   McNamara, Dennis ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

HEART DILATATION; HEART FAILURE; HUMAN; MEDICAL RESEARCH; MYOCARDITIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART-ASSIST DEVICES; HUMANS; IMMUNOSUPPRESSION; MYOCARDITIS; PREVALENCE;

EID: 0034626987     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011093431908     Document Type: Review

References (149)

1. Changing concepts of myocardial diseases
2. Myocarditis: A general review, with an analysis of two hundred and forty cases
3. Severe generalized disease (encephalohepatomyocarditis) occurring in the newborn period and due to infection with Coxsackie virus, group B: Evidence of intrauterine infection with this agent
4. An experimental approach to virus myocarditis
5. Adult heart disease due to Coxsackie virus group B
6. A clinical trial of immunosuppressive therapy for myocarditis
7. Diagnosis and classification of myocarditis by endomyocardial biopsy
8. Nonrheumatic inflammatory diseases of heart
9. Viral myocarditis: Balance between viral infection and immune response
10. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction
11. From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future
12. Coxsackie B5 virus infections during 1965: A report to the director of the Public Health Laboratory Service from various laboratories in the United Kingdom
13. Sudden unexpected death in persons less than 40 years of age
14. Sudden cardiac death in young athletes: A review
15. Sudden cardiac death in Air Force recruits: A 20-year review
16. An increase in sudden unexpected cardiac deaths among young Swedish orienteers during 1979-1992
17. Myocarditis and myocardosis: A clinico-pathologic appraisal
18. Myocarditis: A classification of 1402 cases
19. Techniques for right and left ventricular endomyocardial biopsy
20. Myocarditis and endomyocardial biopsy in unexplained heart failure: A diagnosis in search of a disease
21. Myocarditis in children with dilated cardiomyopathy: Incidence and outcome after dual therapy immunosuppression
22. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis: Whither the gold standard?
23. Myocarditis: A histopathologic definition and classification
24. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results
25. Clinicopathologic description of myocarditis
26. Innovative drug treatments for viral and autoimmune myocarditis
27. Recognition and optimum management of myocarditis
28. Antibodies to Coxsackie B viruses in congestive cardiomyopathy
29. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy
30. Detection of enteroviral ribonucleic acid in myocardial biopsies from patients with idiopathic dilated cardiomyopathy by polymerase chain reaction
31. Molecular detection and differentiation of enteroviruses in endomyocardial biopsies and pericardial effusions from dilated cardiomyopathy and myocarditis
32. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats
33. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy
34. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction
35. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy
36. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome
37. Left ventricular structure and function in children infected with human immunodeficiency virus: The prospective P2C2 HIV Multicenter Study
38. Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: Detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue
39. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients
40. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease
41. Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector
42. Dilated cardiomyopathy associated with hepatitis C virus infection
43. Chronic variation of myocarditis associated with hepatitis C virus infection
44. Hepatitis C virus infection and chronic active myocarditis
45. Low prevalence of hepatitis C virus antibodies and RNA in patients with myocarditis and dilated cardiomyopathy
46. The Southern Cone Initiative against Chagas disease
47. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis
48. Pharmacotoxic myocardial disease: An endomyocardial study
49. Drug-induced heart failure
50. Doxorubicin-induced cardiomyopathy
51. Idiopathic giant-cell myocarditis - Natural history and treatment
52. Giant cell myocarditis: An entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells
53. Hypersensitivity myocarditis
54. Drug related myocarditis. I. Hypersensitivity myocarditis
55. Animal models: Immunological aspects
56. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis
57. Residual pathologic changes following murine coxsackie A and B myocarditis
58. An animal model of congestive (dilated) cardiomyopathy: Dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus
59. Effects of a nitric oxide synthase inhibitor on vasopressin and atrial natriuretic hormone release, thermogenesis and cardiovascular functions in response to interleukin-1 beta in rats
60. Murine natural killer cells limit coxsackie virus B3 replication
61. Coxsackievirus B3-induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance
62. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice
63. Increased susceptibility to coxsackieviral myocarditis in IRF-1 transgenic knockout mice
64. The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis
65. Low-dose N(ω)-nitro-L-arginine methyl ester treatment improves survival rate and decreases myocardial injury in a murine model of viral myocarditis induced by coxsackievirus B3
66. Insights into the ontogeny and activation of T cells
67. Expression of major histocompatibillty complex class I antigen in routine ventricular myocytes infected with Coxsackievirus B3
68. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
69. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3
70. Effects of prednisolone on acute viral myocarditis in mice
71. The immune system in viral myocarditis: Maintaining the balance
72. Experimental CVB3-induced chronic myocarditis in two marine strains: Evidence of interrelationships between virus replication and myocardial damage in persistent cardiac infection
73. Effects of in vivo administration of anti-B7-1/B7-2 monodonal antibodies on murine acute myocarditis caused by coxsackievirus B3
74. Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection
75. Cardiac myosin induces myocarditis in genetically predisposed mice
76. Autoimmune myocarditis induced in mice by cardiac C-protein: Cloning of complementary DNA encoding murine cardiac C-protein and partial characterization of the antigenic peptides
77. Streptococcal M protein peptide with similarity to myosin induces CD4+ T cell-dependent myocarditis in MRL/+ + mice and induces partial tolerance against coxsackieviral myocarditis
78. Cardiac myosin-induced myocarditis: Target recognition by autore-active T cells requires prior activation of cardiac interstitial cells
79. Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction
80. Autoimmune response in chronic ongoing myocarditis demonstrated by heterotopic cardiac transplantation in mice
81. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin
82. Autoimmunity in myocarditis: Relevance of animal models
83. Molecular mimicry: Can epitope mimicry induce autoimmune disease?
84. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis: A possible mechanism through inhibition of nitric oxide production
85. Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis
86. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis
87. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced routine myocarditis
88. T-lymphocyte subsets in idiopathic dilated cardiomyopathy
89. Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy: Relevance for autoimmunity?
90. Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression
91. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases
92. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy
93. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy
94. Cardiac myosin and autoimmune myocarditis
95. Quantitative assessment of antilaminin antibodies in myocarditis and perimyocarditis
96. Autoantibodies against β-adreno-receptors in human idiopathic dilated cardiomyopathy
97. Autoimmunity in idiopathic dilated cardiomyopathy: Characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect
98. 1-adrenergic receptor expression in neonatal rat cardiomyocytes
99. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease
100. Autoantibodies in sera of patients with myocarditis: Characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis
101. Familial dilated cardiomyopathy: Cardiac abnormalities are common in asymptomatic relatives and may represent early disease
102. Circulating heart autoantibodies in familial as compared with nonfamilial idiopathic dilated cardiomyopathy
103. Evidence from family studies for autoimmunity in dilated cardiomyopathy
104. T-cell receptor gene polymorphisms in familial cardiomyopathy: Correlation with anti-β-receptor autoantibodies
105. Active myocarditis in the spectrum of acute dilated cardiomyopathies: Clinical features, histologic correlates, and clinical outcome
106. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: Diagnosis with endomyocardial biopsy and response to immunosuppression
107. Viral myocarditis mimicking acute myocardial infarction
108. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy
109. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis
110. Intervention in myocarditis and acute cardiomyopathy with immune globulin: Results from the randomized placebo controlled IMAC trial
111. Gamma-globulin treatment of acute myocarditis in the pediatric population
112. Peripartum myocarditis and cardiomyopathy
113. Intravenous immune globulin in the therapy of peripartum cardiomyopathy
114. Role of cardiac biopsy in the diagnosis and management of cardiac disease
115. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure: Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis
116. How can myocarditis be diagnosed and should it be treated?
117. Elevations of cardiac troponin I associated with myocarditis: Experimental and clinical correlates
118. Immunohistological diagnosis of myocarditis: Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury
119. Cardiac troponin T in patients with clinically suspected myocarditis
120. Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value
121. Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy
122. Study on microbial persistence in end-stage idiopathic dilated cardiomyopathy
123. Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis
124. Antimyosin antibody cardiac imaging: Its role in the diagnosis of myocardiris
125. Active myocardial damage without attending inflammatory response in dilated cardiomyopathy
126. Antimyosin scintigraphy and immunohistologic analysis of endomyocardial biopsy in patients with clinically suspected myocarditis - Evidence of myocardial cell damage and inflammation in the absence of histologic signs of myocarditis
127. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis
128. Clinical value of echocardiographic tissue characterization in the diagnosis of myocarditis
129. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
130. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: A possible mechanism of digitalis toxicity
131. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy
132. Diagnosing and treating active myocarditis
133. Long-term outcome of patients with biopsy-proved myocarditis: Comparison with idiopathic dilated cardiomyopathy
134. Recently diagnosed idiopathic dilated cardiomyopathy: Incidence of myocarditis and efficacy of prednisone therapy
135. Heart Failure Society of America (HFSA) practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacologic approaches
136. Histologic and cytokine response to immunosuppression in giant-cell myocarditis
137. Management of acute fulminant myocarditis using circulatory support systems
138. MEDOS HIA-VAD biventricular assist device for bridge to recovery in fulminant myocarditis
139. Temporary mechanical support with the BVS 5000 assist device during treatment of acute myocarditis
140. Usefulness of extracorporeal membrane oxygenation for treatment of fulminant myocarditis and circulatory collapse
141. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure
142. Regression of cellular hypertrophy after left ventricular assist device support
143. Successful treatment of severe cytomegalovirus infection with ganciclovir in an immunocompetent host
144. Successful treatment of Epstein-Burr virus infection associated with myocarditis
145. Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha
146. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID)
147. A group B coxsackievirus/poliovirus 5' nontranslated region chimera can act as an attenuated vaccine strain in mice
148. The efficacy of an experimental oil-adjuvanted encephalomyocarditis vaccine in elephants, mice and pigs